DIANTHUS THERAPEUTICS

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

04 نوفمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

15 أكتوبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

04 سبتمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

08 أغسطس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

28 يونيو 2024 10:30:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

12 يونيو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

30 مايو 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

09 مايو 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

08 مايو 2024 15:30:54 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 مايو 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

11 أبريل 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 أبريل 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

21 مارس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 مارس 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

26 فبراير 2024 06:00:00 بحسب Nasdaq GlobeNewswire